Navigation Links
Gamma interferon could aid fight against fungal infections
Date:10/31/2007

Interferon, the superhero cure for viral infections, may be a strong weapon in the battle against fungal infections in immunocompromised patients, according to an article in the November issue of Microbiology Today.

Fungal infections (mycoses) were once seen as exotic diseases, but this is changing rapidly. Although rarely life-threatening in healthy patients, fungal infections are a major problem for the immunocompromised, including HIV patients and people receiving chemotherapy for cancer. Treatment is becoming difficult due to fungal resistance to the antifungal therapy, the variety of disease-causing fungi found and the toxic effects of conventional therapy.

Now, scientists believe gamma interferon, a protein molecule produced by human cells in response to infections, may help to fight fungal infections. Immune cells called neutrophils are rapidly recruited to the site of infection and play an essential role in fungal killing, say Drs. Javier Capilla, Karl Clemons and David Stevens, of Santa Clara Valley Medical Center, Stanford Medical School and the California Institute for Medical Research. Gamma interferon enhances the mechanisms of these cells to make them more potent killers of fungi.

Tests on many fungal infections, including blastomycosis, candidosis and aspergillosis have shown that gamma interferon has beneficial effects in terms of the reduction of the fungus in the organs and on animal survival. But according to Dr Stevens, interferon is not the only answer. Therapy using gamma interferon alone has failed to clear the fungus completely from infected tissues but it has great potential to add to conventional therapy.

When gamma interferon was given to mice infected with Cryptococcus along with amphotericin B, a standard antifungal treatment, the rate of cure was significantly higher than using one therapy alone. We need to look at the route of administration, the frequency of dosing and the dosage given before we can determine fully the use of gamma interferon as an adjunctive therapy.

There is still work to be done. We explored the possibility of using gene therapy for delivering gamma interferon into the nervous system to combat fungal meningitis. Studies of this type suggest a potential clinical use for specific gamma interferon gene therapy in the future. Treatment with gamma-interferon offers a new additional approach to treatment and it provides a new approach to treating difficult diseases. However, clinical trials must document the benefit for patients says Dr Stevens.

Other features in the November 2007 issue of Microbiology Today include:

  • Interferon: The Early Days (page 156)
  • Viruses and Interferon 50 years on (page 160)
  • Chemokines, receptors and virus infection (page 164)
  • Gamma interferon key, but not sufficient for protection against TB" (page 172)
  • Comment: Microbiology a degree of concern (page 200)

These are just some of the articles that appear, together with all the regular features and reports of Society activities.


'/>"/>

Contact: Lucy Goodchild
l.goodchild@sgm.ac.uk
01-189-881-843
Society for General Microbiology
Source:Eurekalert

Related biology news :

1. Genes In The Interferon System Important In Systemic Lupus Erythematosus
2. Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients
3. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
4. Newfound roadblock to interferon effectiveness against malignant melanoma
5. Greasing interferons gears may pave way to greater therapeutic benefits, fewer side effects
6. Protein discovery could unlock the secret to better TB treatment
7. Tiny particles could solve billion-dollar problem
8. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
9. Spider Venom Could Yield Eco-Friendly Insecticides
10. First atlas of key brain genes could speed research on cancer, neurological diseases
11. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... ... , ... Last week, Callan Capital, an integrated wealth management firm specializing in ... San Diego Life Science event at the Estancia La Jolla Resort and Spa. , ... speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former ...
(Date:5/23/2016)... , May 23, 2016 Oxitec CEO ... th at 10:15 a.m. ET before the United States ... genetically engineered mosquitos can play in controlling the spread of ... the Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ... mosquito with a self-limiting gene. Trials in Brazil ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology: